Mannkind Corporation (MNKD) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Mannkind Corporation  (NASDAQ: MNKD)


Mannkind's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Mannkind's ROI in the second quarter of 2026?
Mannkind Corporation recorded a cumulative net loss of $-44 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -7.91%.

Within the Healthcare sector 228 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2788 to 2850.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 69.92 % 40.69 % 10.48 % -14.35 % -3.11 %
Y / Y Net Income Change TTM - - -65.43 % 206.55 % -
Investment (TTM) in Millions 589 610 621 386 300
Return On Investment (TTM) -7.91 % -4.99 % 1.47 % 9.05 % 10.11 %
MNKD's Overall Ranking # 2850 # 2788 # 1558 # 947 # 722
Seq. Investment Change TTM 15.11 % 19.72 % 23.94 % -0.51 % -4.7 %
Seq. Net Income Change TTM - - -79.94 % -10.87 % 8.91 %
Net Income (TTM) in Millions -44 -24 6 29 33

MNKD Company Profile >> Back to MNKD Roi Comparisons >> See Annual MNKD Return On Investment



Return On Investment MNKD's Ranking
Within: No.
Industry # 80
Sector # 229
Overall # 2850

Return On Investment Statistics
High Average Low
593.06 %
-214.48 %
-1693.72 %
(Jun 30 2017)   (Jun 30 2018)



  News about Mannkind Corporation Return on Investment ROI

Augmenting Diabetes Care Study Shows Inhaled Insulin Helps More Adults with Type 1 Diabetes Achieve A1...

September 30, 2024

Breakthrough Study Reveals Positive Impact of Inhaled Insulin on A1C Goals for Adults with Type 1 DiabetesRecent findings from a pivotal study have unveiled encouraging results regarding the management of Type 1 diabetes. More adults with this chronic condition who transitioned from traditional insulin delivery methods specifically multiple daily injections (MDI) or automated insulin pumps reported achieving their glycemic control goals with the use of inhaled insulin, known as Afrezza. This novel delivery method not only simplifies the management of diabetes but also offers a viable alternative for patients struggling to maintain their A1C levels below the critical threshold of 7%. In conjunction with the published findings, the INHALE-3 study results were presented during the American Diabetes Association’s (ADA) 84th Scientific Sessions, illustrating further insights into the efficacy of inhaled insulin versus standard care practices. Achieving A1C Goals: A Closer Look at the Findings The latest press release highlighted that, following the switch to Afrezza, more adults with Type 1 diabetes were able to reach their A1C goal of less than 7%. This data stands alongside the previously disclosed results from the INHALE-3 study, which presented a head-to-head comparison of inhaled insulin and conventional care methods. The findings reveal a promising trajectory for those who have struggled with achieving optimal blood glucose control through traditional routes.

MannKind Corporation Secures PMDA Clearance for Phase 3 Trial of Clofazimine Inhalation Suspension in Japan

September 18, 2024

News MannKind Corporation (NASDAQ: MNKD) has announced that it has received clearance from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to initiate a Phase 3 clinical trial, known as ICoN-1, evaluating clofazimine inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. This pivotal trial marks a significant milestone in MannKind s commitment to addressing unmet medical needs in respiratory medicine, particularly for patients suffering from NTM lung infections.Nontuberculous mycobacterial lung disease poses a considerable challenge for patients and healthcare providers, said a spokesperson for MannKind. We are excited to advance our clinical program in Japan and believe that clofazimine inhalation suspension could offer a new treatment option for those affected by this condition.





Financial Statements
Mannkind's II. Quarter Investments $ 589 Millions MNKD's Balance sheet
Mannkind's II. Quarter Income $ -19 Millions Quarterly MNKD's Income Statement
MNKD's Income by Division See MNKD's Income by Division


MNKD Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 621 312 371 0 273
Y / Y Investment Growth 99.08 % -15.92 % - - 681.63 %
Net Income in Millions 6 28 -12 -87 -81
Y / Y Net Income Growth -78.75 % - - - -
Annual Return On Investment 0.94 % 8.84 % -3.22 % - -29.66 %


Annual Roi Comment
In the fiscal year 2025 ROI decreased relative to the previous year to 0.94 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
MNKD's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for MNKD's Competitors
Subscribers only: Roi for Mannkind's Suppliers
Subscribers only: Return On Investment for MNKD's Customers

Other Ratios
MNKD's Roa MNKD's Inventory Turnover Ratio MNKD's Growth Rates MNKD's Dividend Statistics
MNKD's Profitability Ratios MNKD's Asset Turnover Ratio MNKD's Dividend Growth
MNKD's Roe MNKD's Valuation Ratios MNKD's Financial Strength Ratios MNKD's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-11T09:42:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.